# CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission

> **NCT01639456** · PHASE2 · WITHDRAWN · sponsor: **Masonic Cancer Center, University of Minnesota**

## Conditions studied

- Acute Myelogenous Leukemia

## Interventions

- **BIOLOGICAL:** CD3-/CD19- natural killer cells
- **BIOLOGICAL:** CD3-CD56+ natural killer cells
- **DEVICE:** CliniMACS® CD3 and CD19 Reagent System
- **DEVICE:** CliniMACS® CD56 Reagent System
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Aldesleukin

## Key facts

- **NCT ID:** NCT01639456
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-10
- **Primary completion:** 2017-01
- **Final completion:** 2017-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** study was abandoned and a new study was written to replace this one
- **Last updated:** 2017-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01639456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01639456, "CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01639456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*